Skip to main content
. 2021 Oct 30;23:524–538. doi: 10.1016/j.omtm.2021.10.011

Figure 5.

Figure 5

Cohort of 6 SMA patients receiving co-therapy with nusinersen and onasemnogene abeparvovec early in life

Longitudinal plots for pNf-H concentrations, Nf-L concentrations, and CMAP values for each individual case (A–F) in this cohort. Red arrows indicate the first nusinersen dose and dark arrows indicate the onasemnogene abeparvovec injection. ∗Subject 913 received only a single loading dose of nusinersen (please see materials and methods for details).